The MAHOGANY trial (NCT04082364) is currently evaluating the use of margetuximab (a monoclonal Fc-optimized HER2 antibody) plus retifanlimab (an anti-PD-1 antibody) with and without chemotherapy in unresectable GC and GEJC [73]. This evidence concerns the gene ERBB2 and gastric cancer.